Immunocore Holdings (STU:6YG) FCF Margin % : 25.29% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Immunocore Holdings's Free Cash Flow for the three months ended in Sep. 2024 was €18.3 Mil. Immunocore Holdings's Revenue for the three months ended in Sep. 2024 was €72.3 Mil. Therefore, Immunocore Holdings's FCF Margin % for the quarter that ended in Sep. 2024 was 25.29%.

As of today, Immunocore Holdings's current FCF Yield % is 1.30%.

The historical rank and industry rank for Immunocore Holdings's FCF Margin % or its related term are showing as below:

STU:6YG' s FCF Margin % Range Over the Past 10 Years
Min: -417.54 Med: -149.42 Max: 6.69
Current: 6.69

During the past 6 years, the highest FCF Margin % of Immunocore Holdings was 6.69%. The lowest was -417.54%. And the median was -149.42%.

STU:6YG's FCF Margin % is ranked better than
83.54% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs STU:6YG: 6.69

Immunocore Holdings FCF Margin % Historical Data

The historical data trend for Immunocore Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings FCF Margin % Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-417.54

-213.60

-396.05

-29.49

-1.00

Immunocore Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															15.23	-26.44	-7.12	30.69	25.29

Competitive Comparison of Immunocore Holdings's FCF Margin %

For the Biotechnology subindustry, Immunocore Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's FCF Margin % falls into.

Immunocore Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Immunocore Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.279	/	228.725
	=	-1.00 %

Immunocore Holdings's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	18.289	/	72.303
	=	25.29 %

Immunocore Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (STU:6YG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IMCR:USA

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Immunocore Holdings Headlines

No Headlines